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Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce
Wave Reﬂections, Left Ventricular Hypertrophy, or Myocardial Fibrosis
in Patients With Heart Failure With Preserved Ejection Fraction
Payman Zamani, MD, MTR; Scott Akers, MD, PhD; Haideliza Soto-Calderon, BA; Melissa Beraun, MD; Maheswara R. Koppula, MD;
Swapna Varakantam, MD; Deepa Rawat, MD; Prithvi Shiva-Kumar, MD, MS, MBA; Philip G. Haines, MD, MTR; Jesse Chittams, MS;
Raymond R. Townsend, MD; Walter R. Witschey, PhD; Patrick Segers, PhD; Julio A. Chirinos, MD, PhD
Background-—Wave reﬂections, which are increased in patients with heart failure with preserved ejection fraction, impair diastolic
function and promote pathologic myocardial remodeling. Organic nitrates reduce wave reﬂections acutely, but whether this is
sustained chronically or affected by hydralazine coadministration is unknown.
Methods and Results-—We randomized 44 patients with heart failure with preserved ejection fraction in a double-blinded fashion to
isosorbide dinitrate (ISDN; n=13), ISDN+hydralazine (ISDN+hydral; n=15), or placebo (n=16) for 6 months. The primary end point was
the change in reﬂection magnitude (RM; assessed with arterial tonometry and Doppler echocardiography). Secondary end points
included change in left ventricular mass and ﬁbrosis, measured with cardiac magnetic resonance imaging, and the 6-minute walk
distance. ISDN reduced aortic characteristic impedance (mean baseline=0.15 [95% CI, 0.14–0.17], 3 months=0.11 [95% CI, 0.10–
0.13], 6 months=0.10 [95% CI, 0.08–0.12] mm Hg/mL per second; P=0.003) and forward wave amplitude (Pf, mean baseline=54.8
[95% CI, 47.6–62.0], 3 months=42.2 [95% CI, 33.2–51.3]; 6 months=37.0 [95% CI, 27.2–46.8] mm Hg, P=0.04), but had no effect on
RM (P=0.64), left ventricular mass (P=0.33), or ﬁbrosis (P=0.63). ISDN+hydral increased RM (mean baseline=0.39 [95% CI, 0.35–
0.43]; 3 months=0.31 [95% CI, 0.25–0.36]; 6 months=0.44 [95% CI, 0.37–0.51], P=0.03), reduced 6-minute walk distance (mean
baseline=343.3 [95% CI, 319.2–367.4]; 6 months=277.0 [95% CI, 242.7–311.4] meters, P=0.022), and increased native myocardial
T1 (mean baseline=1016.2 [95% CI, 1002.7–1029.7]; 6 months=1054.5 [95% CI, 1036.5–1072.3], P=0.021). A high proportion of
patients experienced adverse events with active therapy (ISDN=61.5%, ISDN+hydral=60.0%; placebo=12.5%; P=0.007).
Conclusions-—ISDN, with or without hydralazine, does not exert beneﬁcial effects on RM, left ventricular remodeling, or
submaximal exercise and is poorly tolerated. ISDN+hydral appears to have deleterious effects on RM, myocardial remodeling, and
submaximal exercise. Our ﬁndings do not support the routine use of these vasodilators in patients with heart failure with preserved
ejection fraction.
Clinical Trial Registration-—URL: http:www.clinicaltrials.gov. Unique identiﬁer: NCT01516346. ( J Am Heart Assoc. 2017;6:
e004262. DOI: 10.1161/JAHA.116.004262.)
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H eart failure with preserved ejection fraction (HFpEF) isan epidemic condition for which the underlying mech-
anisms are incompletely understood. Epidemiologic data
demonstrate a greater prevalence of hypertension, advanced
age, and vascular risk factors such as renal dysfunction and
diabetes, in patients with HFpEF,1–4 all of which increase
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vascular stiffness and pulsatile loading on the left ventricle.5
Observational data demonstrate increased pulsatile load and
wave reﬂections in patients with HFpEF,6–9 which correlate
with decreased exercise capacity, a fundamental feature of
the disease.9,10
Wave reﬂections, arising from the gradual increase in
impedance along the arterial tree and from discrete sites of
impedance mismatch, augment late systolic load on the left
ventricle.11,12 Late systolic load increases left ventricular (LV)
mass and ﬁbrosis and worsens diastolic function in animal
models.13,14 Late systolic load is also associated with
increased LV mass and geometry15 and impaired systolic
and diastolic function in humans.16–18 Furthermore, the
reduction in reﬂection magnitude (RM) correlates with
reductions in LV mass during antihypertensive therapy.19
Organic nitrates have been shown to blunt wave reﬂections
in short-term studies,20–23 although tolerance remains a
concern with chronic administration.24 However, therapy with
hydralazine has been shown to attenuate this tolerance.24–26
Whether organic nitrates can modulate wave reﬂections
chronically and whether this effect is modulated by
hydralazine is unknown. Furthermore, the effects of long-
term nitrate therapy on arterial hemodynamics, LV remodel-
ing, diastolic function, and exercise capacity in patients with
HFpEF are unknown. We designed the current pilot trial to test
whether the organic nitrate isosorbide dinitrate (ISDN), with or
without hydralazine, blunts wave reﬂections, thereby leading
to improvements in myocardial structure and function.
Methods
Inclusion/Exclusion Criteria
Inclusion criteria included symptomatic heart failure with a
preserved ejection fraction (LV ejection fraction >50%), in
addition to at least one of the following: (1) prior hospital-
ization for decompensated heart failure; (2) acute treatment
for heart failure requiring intravenous diuretics or hemoﬁltra-
tion; (3) echocardiographic evidence for elevated ﬁlling
pressures27; (4) chronic treatment with a loop diuretic for
control of symptoms; (5) or an elevated N-terminal pro-brain
natriuretic peptide (NT-pro-BNP) level. Patients were required
to be on stable medical therapy for the past month. Exclusion
criteria included any rhythm other than sinus with native
conduction; noncardiac conditions that signiﬁcantly limited
exercise (orthopedic or neuromuscular); known hypertrophic,
inﬁltrative, or inﬂammatory cardiomyopathy; pericardial dis-
ease; signiﬁcant pulmonary disease; primary pulmonary
arteriopathy; acute coronary syndrome or coronary revascu-
larization within the past 60 days; clinically signiﬁcant
perfusion defects on stress imaging without subsequent
revascularization; signiﬁcant valvular disease (eg, moderate or
greater mitral regurgitation or aortic stenosis); uncontrolled
hypertension (systolic blood pressure >180 mm Hg or dias-
tolic blood pressure >100 mm Hg); prior reduced LV ejection
fraction <50%; hemoglobin <10 g/dL; current therapy with
organic nitrates or hydralazine; and elevations on liver
function test results. Additional exclusion criteria for the
cardiac magnetic resonance imaging (MRI) included impaired
renal function precluding the administration of gadolinium
(estimated glomerular ﬁltration rate <30 mL/min per
1.73 m2) and signiﬁcant claustrophobia.
Study Design
This was a randomized double-blinded pilot clinical trial of
ISDN (40 mg 3 times daily), ISDN plus hydralazine (ISDN
40 mg+hydral 75 mg, 3 times daily), or placebo (PB). The
doses selected were based on A-HeFT (the African-American
Heart Failure Trial), which demonstrated a beneﬁt with these
doses of ISDN+hydral in black patients with HFrEF.28 We
tested the hypothesis that chronic administration of ISDN,
with or without hydralazine, would blunt wave reﬂections. Our
primary end point was the change in RM, assessed 6 months
after study initiation. Key secondary end points included
change in LV mass and diffuse interstitial myocardial ﬁbrosis
measured by MRI, change in 6-minute walk (6MW) distance,
change in diastolic function, change in NT-pro-BNP, and
change in quality of life assessed by the Kansas City
Cardiomyopathy Questionnaire. This protocol was approved
by the institutional review boards of the Philadelphia Veterans
Affairs Hospital and the Hospital of the University of
Pennsylvania. All patients provided written informed consent.
The trial was registered at ClinicalTrials.gov (www.ClinicalTria
ls.gov, NCT01516346).
After randomization, patients were started on half of the
intended target dose. After 1 week, patients were reassessed,
and the doses of study medications were increased unless
orthostatic hypotension or other limiting side effect was
present. Study medications were continued for 6 months. The
ﬁrst patient was enrolled in March 2012, and the ﬁnal study
visit was conducted in December 2015.
Cardiac MRI—LV Structure and Function
Participants underwent a cardiac MRI examination at baseline
and at 6 months to assess LV structure and function using a
1.5 Tesla (T) whole-body MRI scanner (Avanto or Espree,
Siemens Healthcare, Malvern, Pennsylvania) equipped with a
phased-array cardiac coil. LV volumes and ejection fractions
were determined using balanced steady-state free-precession
cine imaging. Typical parameters were as follows: repetition
time=2.6 ms; echo time=1.3 ms; phases=30; slice thick-
ness=8 mm; bandwidth=898 Hz/pixel, ﬂip angle=70°, ﬁeld of
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view=300 to 340 mm2, matrix size=1929192; and parallel
imaging factor=2. LV short-axis stack cine images were
manually traced at end-diastole and end-systole using CMR42
software (Circle CVI, Calgary, Alberta, Canada). LV mass was
computed as the difference between epicardial and endocar-
dial volumes, multiplied by myocardial density, and was
measured at end-diastole and end-systole with the results
averaged. LV mass was normalized for height in meters raised
to the power of 1.7.29 Stroke volume was computed as the
difference between the end-diastolic and end-systolic vol-
umes. End-diastolic volume (EDV) and stroke volume were
indexed to body surface area.
We used a modiﬁed Look-Locker inversion recovery
(MOLLI) sequence to assess T1 times prior to and following
the intravenous administration of gadolinium contrast
(gadopentetate dimeglumine, 0.15 mmol/kg or equivalent)
in a midventricular short-axis slice.30,31 Scan parameters for
MOLLI were: ﬁeld of view=340 mm2; matrix size=1449192;
slice thickness=6 mm; repetition time=2.4 ms; echo
time=1.18 ms; ﬂip angle=30°; bandwidth=1000 Hz/pixel;
and parallel imaging=2. Myocardial T1 measurements were
performed before and at several time points (5, 10, 15, and
20–40 minutes) after gadolinium administration. MOLLI was
performed with a 5-3-3 schema (2 inversions, 5 TIs after
inversion 1, 3 T1 recovery heartbeats, and 3 TIs after
inversion 2). All available blood and myocardial T1 measure-
ments were used to compute lambda (k, the myocardium-
blood partition coefﬁcient) as the slope of the myocardial
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Figure 1. Arterial tonometry and ﬂow methods for input impedance and wave separation analysis. Carotid tonometry (top left) and pulsed wave
Doppler (top right) are used to obtain signal-averaged pressure and ﬂow waveforms (middle panel). Aortic root characteristic impedance (Zc) is
computed in the frequency domain as the mean value of the modulus of higher harmonics (bottom left panel, dashed line). In the middle panel, the
ﬂow waveform is displayed in the pressure axis as the ﬂow9Zc. This can be seen as the minimum pulse pressure required to eject the observed
ﬂow across the local aortic root impedance, in the complete absence of wave reﬂections. Additional pressure is related to wave reﬂections arising
from more distal segments. The bottom right panel displays separation of the measured pressure wave into forward (Pf, blue) and backward
components (Pb, green) components; the reﬂection magnitude is computed as the ratio of Pb/Pf. LVOT indicates left ventricular outﬂow tract.
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1/T1 over the blood 1/T1 change, via linear regression.31 The
percent of myocardial tissue comprised by the extracellular
space (extracellular volume fraction [ECV], %)=k9(1hema-
tocrit). As heart rate correction did not appreciably affect the
results, only the noncorrected values are presented.
Echocardiography and Arterial Tonometry
Echocardiography with arterial tonometry was performed at
baseline, after 3 months, and at the ﬁnal 6-month visit.
Echocardiography was performed using a Vivid e9 or Vivid I
machine (General Electric, Fairﬁeld, CT). Diastolic function
was assessed according to American Society of Echocardio-
graphy criteria.27 Each metric was quantiﬁed in triplicate with
average values presented. Left atrial volume was quantiﬁed
using the area-length method and indexed to body surface
area (left atrial volume index).32 Volumetric ﬂow was
quantiﬁed using pulse-wave Doppler measurements from the
left ventricular outﬂow tract in the 5-chamber view and the
left ventricular outﬂow tract cross-sectional area computed
from its diameter measured in the parasternal long-axis view.
Applanation tonometry was performed at the carotid,
radial, and femoral arteries using a high-ﬁdelity tonometer
(Millar Instruments, Houston, TX), with a single-lead ECG used
as a ﬁducial point. Surface measurements were obtained from
the sternal notch to the site of interrogation at the carotid and
femoral arteries to compute pulse wave velocity. Radial
tonometry was calibrated using the brachial systolic blood
pressure and diastolic blood pressure, obtained using a
validated oscillometric device (Omron HEM-705CP, Omron
Corp, Kyoto, Japan or Accutorr Plus, Datascope Corp.,
Paramus, NJ). Mean arterial pressure was computed as the
mean pressure from the radial pressure waveform. Carotid
tonometry, calibrated using mean arterial pressure and
53 patients
consented
44 started study
medications
9: withdrew before starting 
study medications
- 6 no longer interested
- 1 noncardiac cause of 
dyspnea identified
- 1 more active medical issue
took precedent
- 1 not specified
17: Dropped out after 
starting study medications
- 8 due to side effects
- 4 lost to follow-up
- 3 due to medical 
reasons
- 2 poor compliance
27 completed
study in its entirety
Patients at 
each Time Pt.
Started Study
Medications
3 months Final
ISDN 13 9 7
ISDN+hydral 15 9 9
Placebo 16 12 11
Exclusion Criteria n
Any rhythm other than sinus 143
Inability to exercise 32
Significant valvular disease 62
Hypertrophic/infiltrative 
cardiomyopathy
27
Pericardial disease 3
Pulmonary arterial 
hypertension
27
Recent ischemia 1
Noncardiac dyspnea 90
Uncontrolled HTN 3
Hemoglobin <10 g/dL 26
Cirrhosis 12
Current ischemia or angina 26
Therapy with PDE5-I 13
Use of nitrates 51
eGFR<30/hemodialysis 41
Reduced LVEF 64
Prior reduced LVEF, now 
recovered
37
No symptoms of HF 164
Deceased 90
No recent records available 30
Not interested 90
1085 patients
screened
Figure 2. CONSORT diagram and ﬂow of patients through each study visit. eGFR indicates estimated glomerular ﬁltration rate; HF, heart
failure; HTN, hypertension; hydral, hydralazine; ISDN, isosorbide dinitrate; LVEF, left ventricular ejection fraction; PDE5-I, phosphodiesterase type
5 inhibitor.
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Table 1. Baseline Demographic, Medication, Laboratory, and Imaging Data
Variable
All Participants
(N=44) ISDN (n=13)
ISDN+Hydral
(n=15) Placebo (n=16)
Age, median (IQR), y 62 (59–68) 61 (56–65) 60 (55–66) 66.5 (59.5–72)
Male, No. (%) 31 (70.5) 8 (61.5) 11 (73.3) 12 (75)
Race, No. (%)
Black 27 (61.4) 8 (61.5) 10 (66.7) 9 (56.3)
White 16 (36.4) 4 (30.8) 5 (33.3) 7 (43.8)
Other 1 (2.3) 1 (7.7) 0 (0) 0 (0)
Body mass index (kg/m2), mean (SD) 36.7 (6.2) 35.7 (6.7) 38.2 (5.1) 36.2 (6.8)
Obese, No. (%) 36 (81.8) 10 (76.9) 13 (86.7) 13 (81.3)
Hypertension, No. (%) 40 (90.9) 13 (100) 14 (93.3) 13 (81.3)
Hyperlipidemia, No. (%) 36 (81.8) 10 (76.9) 12 (80.0) 14 (87.5)
Coronary artery disease, No. (%) 16 (36.4) 4 (30.8) 6 (40.0) 6 (37.5)
History of atrial fibrillation/flutter, No. (%) 5 (11.4) 0 (0) 3 (20.0) 2 (12.5)
Diabetes, No. (%) 27 (61.4) 11 (84.6) 6 (40.0) 10 (62.5)
Obstructive sleep apnea, No. (%) 24 (54.6) 6 (46.2) 10 (66.7) 8 (50.0)
Medical therapy
b-Blockers, No. (%) 26 (59.1) 6 (46.2) 9 (60.0) 11 (68.8)
Aspirin, No. (%) 30 (68.2) 10 (76.9) 9 (60.0) 11 (68.8)
ACEI/ARB, No. (%) 29 (65.9) 7 (53.9) 10 (66.7) 12 (75.0)
Loop diuretics, No. (%) 24 (54.6) 6 (46.2) 8 (53.3) 10 (62.5)
Mineralocorticoid receptor antagonists, No. (%) 2 (4.6) 1 (7.7) 1 (6.7) 0 (0)
Calcium channel blockers, No. (%) 19 (43.2) 5 (38.5) 6 (40.0) 8 (50.0)
Thiazide diuretics, No. (%) 16 (36.4) 7 (53.9) 6 (40.0) 3 (18.8)
Statins, No. (%) 29 (65.9) 10 (76.9) 8 (53.3) 11 (68.8)
Baseline laboratories
Hematocrit, mean (SD), % 38.5 (4.9) 39.3 (3.7) 38.6 (4.0) 37.8 (6.4)
eGFR (mL/min per 1.73 m2), mean (SD) 70.3 (26.7) 77.1 (27.1) 70.8 (32.1) 64.4 (21.0)
eGFR <60 mL/min per 1.73 m2, No. (%) 18 (40.9) 5 (38.5) 7 (46.7) 6 (37.5)
NT-pro-BNP, median (IQR), pg/mL 233.0 (90.5–527.0) 154 (88–280) 210 (118–1190) 326 (83.3–720.3)
Elevated NT-pro-BNP, No. (%) 31 (70.5) 9 (69.2) 11 (73.3) 11 (68.8)
Baseline cMRI data
LV mass, median (IQR), g 170.0 (132.9–200.5) 183.3 (136.3–215.5) 168.8 (131.9–198.5) 159.5 (126.6–
215.0)
Indexed LV mass, median (IQR), g/m1.7 64.2 (56.6, 81.2) 68.0 (58.3, 87.2) 60.2 (57.2, 73.9) 63.6 (53.1, 80.7)
LVEDV, mean (SD), mL 171.9 (43.8) 159.1 (39.3) 176.8 (38.9) 179.5 (51.6)
Indexed LVEDV, mean (SD), mL/m2 74.9 (15.2) 71.2 (12.8) 74.0 (13.6) 79.2 (18.4)
LV ejection fraction, median (IQR), % 59.4 (55.1–65.5) 64.1 (57.8–65.9) 56.9 (52.9–67.4) 59.3 (55.5–65.0)
LVECV fraction, mean (SD), % 28.9 (6.6) 28.3 (4.5) 28.6 (8.0) 29.6 (6.8)
Native myocardial T1, mean (SD), s 1013.2 (52.0) 1017.1 (41.3) 1002.0 (43.2) 1019.9 (64.5)
Baseline echocardiographic data
Mitral E velocity, mean (SD), cm/s 81.0 (23.8) 69.4 (21.0) 82.2 (26.7) 89.8 (20.1)
Mitral A velocity, mean (SD), cm/s 77.1 (22.6) 76.7 (19.7) 76.9 (25.2) 77.7 (23.8)
Continued
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diastolic blood pressure, was used to estimate central
pressures. Tonometric signals were processed using Sphyg-
mocor software (AtCor Medical, Australia).
Central Arterial Hemodynamics
Custom-designed software was programmed using MATLAB
(R2014b, MathWorks, Natick, MA) to derive input impedance,
as previously described (Figure 1).33 In brief, central pressure
measurements were ensemble-averaged and time-aligned
with left ventricular outﬂow tract ﬂow such that the upstroke
of pressure and ﬂow occurred simultaneously, peak ﬂow was
coincident with the ﬁrst systolic peak or inﬂection point in the
pressure waveform, and ﬂow ceased at the dicrotic notch.
Characteristic impedance (Zc) was quantiﬁed in the frequency
domain as the average modulus at higher frequencies. Total
vascular resistance was quantiﬁed as the ratio of mean
pressure to mean ﬂow. Total arterial compliance was deter-
mined using the pulse pressure method.33 Linear wave
separation was performed to obtain the amplitude of the
forward (Pf) and backward (Pb) pressure waves. RM was
deﬁned as the ratio of Pb to Pf (Pb/Pf).
Additional Measurements Performed at Baseline
and at 6 Months
The Kansas City Cardiomyopathy Questionnaire was admin-
istered at the baseline and 6-month visits.34 Basic laboratory
tests, including NT-pro-BNP levels (upper limit of nor-
mal=125 pg/mL), were also performed. Patients performed
a 6MW test using the standard protocol.35 The Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation was
used to estimate glomerular ﬁltration rate.36
Statistical Methods
Baseline characteristics are presented as mean (percentage)
or median (interquartile range [IQR]), as appropriate. Mixed-
effects models were generated using the xtreg command in
STATA (Stata/SE version 13.1, StataCorp, College Station,
TX), which incorporates the correlation between repeated
measurements in the same individual. No assumption of
linearity was made, and all available observations were used
to estimate treatment effects. An overall P<0.05 was taken to
be signiﬁcant for each model, with post hoc comparisons
between visits subsequently performed. Study end points are
presented in the tables as marginal means estimated from the
mixed models with 95% CIs. Due to the small number of
patients who completed this pilot study, only intragroup
comparisons were performed. Paired t tests using only data
from the baseline and ﬁnal visits were also performed for
select end points. Given the small sample sizes, the signed
rank test was additionally performed to demonstrate general
agreement. Our study had 80% power to detect a within-group
minimal change of at least 14.4 g/m1.7 in LV mass and 0.10
in RM. Formal between-group comparisons were not per-
formed because of the risk of type II error.
Results
The ﬂow of patients through the study is shown in Figure 2. A
total of 53 patients consented to the study. Of these 53
patients, 9 withdrew before receiving study medications; thus,
44 (83%) patients were randomized and started the study
medications: 13 patients were randomized to ISDN, 15 to
ISDN+hydral, and 16 to PB. Of these individuals, 30 (68%)
provided 3-month central arterial hemodynamics data
(ISDN=9, ISDN+hydral=9, PB=12) and 27 (61%) provided
6-month data (ISDN=7, ISDN+hydral=9, PB=11). Demographic,
echocardiographic, and cardiac MRI data are shown in Table 1.
The median age of patients was 62 (IQR 59–68) years. The
majority of patients were obese (81.8%), hypertensive (90.9%),
and had a history of diabetes (61.4%). A total of 31 (70.5%)
patients had an elevated NT-pro-BNP level, and 40.9% had an
estimated glomerular ﬁltration rate <60 mL/min per 1.73 m2.
Median E/septal e0 ratio was 12.8 (IQR 10.2–15.2), and
the median left atrial volume index was 29.9 (IQR 25.6–38.3)
mL/m2. Aside from the study intervention, there were no
Table 1. Continued
Variable
All Participants
(N=44) ISDN (n=13)
ISDN+Hydral
(n=15) Placebo (n=16)
Mitral E/A ratio, median (IQR) 1.01 (0.83–1.30) 0.83 (0.75–1.08) 1.01 (0.89–1.25) 1.16 (0.88–1.54)
Mitral septal tissue (e0) velocity, mean (SD), cm/s 6.3 (2.1) 6.0 (1.6) 6.3 (2.3) 6.6 (2.3)
Mitral E/e0, median (IQR) 12.8 (10.2–15.2) 11.0 (9.8–12.8) 12.4 (10.2–15.2) 13.5 (11.3–17.3)
Left atrial volume index, median (IQR), mL/m2 29.9 (25.6–38.3) 29.0 (26.0–34.1) 34.3 (22.7–43.5) 31.0 (27.9–35.4)
Elevated N-terminal pro-brain natriuretic peptide (NT-pro-BNP) deﬁned as >125 pg/mL. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; cMRI,
cardiac magnetic resonance imaging; eGFR, estimated glomerular ﬁltration rate; Hydral, hydralazine; IQR, interquartile range; ISDN, isosorbide dinitrate; LV, left ventricular; LVECV, left
ventricular extracellular volume fraction; LVEDV, left ventricular end-diastolic volume.
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signiﬁcant differences in medication usage between the groups
(P>0.10 for all). Compliance was assessed via pill counts. In the
27 patients who completed the study, compliance rates were:
ISDN: 91.8%; ISDN+hydral: 90.2%; and PB: 94.8%. The mean
daily dose of ISDN in the ISDN only group was 111.422.7 mg.
The mean ISDN and hydralazine doses in the combination
group were 100.030.0 mg of ISDN and 187.556.3 mg of
hydralazine. There were no differences in demographic char-
acteristics between those who did versus those who did not
complete the study (data not shown).
Arterial Hemodynamics
Treatment with ISDN did not reduce brachial systolic blood
pressure (P=0.09), yet tended to reduce central systolic blood
pressure (visit 2 versus visit 1: 27.6 [95% CI 54.0 to
1.3]; visit 3 versus visit 1: 30.4 [95% CI 58.2 to 2.6]
mm Hg; overall P=0.051; Table 2), although this reduction did
not reach statistical signiﬁcance. There were no signiﬁcant
changes in brachial or central blood pressures with ISDN+hy-
dral or PB. Heart rate and augmentation index were not
signiﬁcantly altered by any study medication (data not
shown).
ISDN did not reduce RM, the primary end point of the study
(P=0.64; Table 2). In contrast, ISDN reduced aortic Zc
(P=0.003), reduced Pf (P=0.04), and increased total arterial
compliance (P=0.01). Combination therapy with ISDN+hydral
increased RM between the 3- and 6-month visits (P=0.012).
No changes in arterial hemodynamic parameters were
demonstrated in the PB group (Figure 3).
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Figure 3. Changes in end points as compared with baseline (marginal mean differences with standard error presented). A, Reﬂection
magnitude (RM). B, Characteristic impedance (Zc). C, Forward wave magnitude (Pf). D, Total arterial compliance (TAC). E, Six-minute walk (6MW)
distance. F, Native T1 myocardial relaxation time. Hydral indicates hydralazine; ISDN, isosorbide dinitrate.
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LV Mass and Fibrosis
There was no change in LV mass in any of the trial arms
(Table 3). Similarly, there were no changes in ECV, assessed
following the administration of gadolinium, in any of the trial
arms. Combination therapy with ISDN+hydral increased the
native T1 relaxation time (P=0.021).
Other LV Geometric Measures
A reduction in EDV was observed in the ISDN (P=0.037) and
PB (P=0.037) arms (Table 3). This occurred in concert with
reductions in stroke volume for ISDN (P=0.029) and a trend
towards reduced stroke volume in PB (P=0.054). In contrast,
combination therapy with ISDN+hydral tended to increase
EDV (P=0.052) and signiﬁcantly increased stroke volume
(P=0.002).
Additional Assessments
NT-pro-BNP levels, mitral E/septal e0 ratio, left atrial volume
index (Table 4), and the overall summary score for the Kansas
City Cardiomyopathy Questionnaire (Table 5) did not change
in any of the trial arms. The 6MW distance was unchanged in
both the ISDN and PB groups; however, 6MW distance
worsened in the ISDN+hydral arm (baseline 343.3 [95% CI,
319.2–367.4]; ﬁnal 277.0 [95% CI, 242.7–311.4] meters;
P=0.022).
Sensitivity Analyses
Paired analyses using only data from the baseline and ﬁnal
visits were also performed on select end points (Table 6). The
results of these sensitivity analyses were consistent with the
ﬁndings using the mixed models approach.
Adverse Events
Therapy with ISDN or ISDN+hydral was poorly tolerated, with
signiﬁcantly more patients experiencing adverse events in
both active arms as compared with those taking PB (ISDN,
n=8 [61.5%]; ISDN+hydral, n=9 [60.0%], PB, n=2 [12.5%];
P=0.007 [Table 7]). Common side effects in the active
treatment arms were headache, dizziness/lightheadedness,
hypotension, and orthostasis.
Discussion
In this randomized pilot trial, we examined the impact of ISDN,
ISDN+hydral, and PB on wave reﬂections, LV remodeling,
6MW distance, NT-pro-BNP, and quality of life. Contrary to our
hypothesis, ISDN signiﬁcantly reduced aortic Zc and Pf but didTa
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not reduce RM or improve LV remodeling. Moreover, combi-
nation therapy with ISDN+hydral led to an increase in RM, a
decrease in 6MW distance, and adverse myocardial remod-
eling, as demonstrated by increased myocardial native T1
relaxation time. Importantly, ISDN and ISDN+hydral were
poorly tolerated, with an increase in adverse events. Our
study does not support the use of ISDN or ISDN+hydral in
HFpEF.
With LV contraction, a pulse wave is generated that
propagates down the arterial tree. When this wave encounters
sites of impedance mismatch, such as at bifurcations, a
portion of this pulse wave is reﬂected back towards the heart.
Optimally timed wave reﬂections increase diastolic pressure
and coronary perfusion, without exerting pronounced effects
in central systolic pressure or left ventricular load. In
individuals with increased vessel stiffness, the reﬂected wave
arrives back at the heart earlier, increasing the mid-to-late
systolic workload of the left ventricle. This increase in late-
systolic load has been shown to induce LV hypertrophy,13,15
impair systolic16 and diastolic14,16,17 function, and increase
myocardial ﬁbrosis.13 Therapies that reduce RM are associ-
ated with regression in LV mass in hypertensive patients,19
suggesting that RM may be a potential therapeutic target in
HFpEF patients, who are generally hypertensive, and exhibit
prominent wave reﬂections.7,8
In this study, ISDN reduced aortic Zc and Pf but did not
reduce RM. The venodilating effect of ISDN, which would
reduce preload and stroke volume, as well as the effects of
this drug on aortic Zc, can explain the reduction in Pf, yet the
neutral effects on RM bear additional mention. It is possible
that chronic administration of organic nitrate led to increased
oxidative stress and worsened endothelial dysfunction,
reducing nitric oxide bioavailability37,38 and mitigating any
long-term beneﬁt on wave reﬂections. This mechanism could
be particularly prominent in HFpEF patients, a population in
which oxidative stress and decreased nitric oxide bioavail-
ability have been demonstrated.39,40 Second, the long-term
administration of ISDN could exert hemodynamic effects on
multiple arterial segments, with differential impact on RM.
ISDN reduced aortic Zc, which may have counteracted the
vasodilatory effects on more distal vessels, such as the
muscular arteries. Consequently, overall impedance matching
may have been unchanged, leading to similar RM.41,42 Finally,
differences in the vasculature of HFpEF patients may have led
to different responses than that which occurs in patients with
hypertension or HFrEF.
An unexpected ﬁnding of our study was the increase in RM
seen after 6 months of ISDN+hydral administration, along
with reduced 6MW distances, increased EDV, and increased
native T1 relaxation time. Prior work in a small number of HF
patients found no change in sodium excretion following 3
days of hydralazine, although renin activity increased.43 InTa
bl
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V-HeFT II (the Vasodilator-Heart Failure Trial), treatment with
ISDN+hydral increased norepinephrine levels.44 More
recently, hydralazine has been shown to activate pregan-
glionic sympathetic neurons.45 Our ﬁndings of increased
preload (suggesting volume retention), adverse interstitial
remodeling, and reduced 6MW distances may be consistent
with sympathetic nervous system activation.46–48 Other
manifestations of sympathetic activation, such as tachycardia,
could have been masked by the high utilization of concomi-
tant cardiovascular medications, such as b-blockers.
In our study, we found a signiﬁcant increase in pregadolin-
ium native T1 time in the ISDN+hydral group, in the absence
of an increase in extracellular volume fraction, assessed
following the administration of gadolinium. Several explana-
tions may underlie this ﬁnding. First, ECV calculations reﬂect
interstitial changes, given its reliance on gadolinium, an
extracellular contrast agent.49 Native T1 signals, however,
arise from the entirety of the myocardium, and thus reﬂect
both the intracellular as well as the interstitial spaces.50 The
increased native T1 time, in the absence of a change in ECV,
may thus be a reﬂection of changes occurring at the
intracellular level (cardiomyocytes, cardiac ﬁbroblasts,
smooth muscle cells, and endothelial cells), including
increased edema or cardiomyocyte disarray.50,51
Finally, treatment with ISDN, with or without hydralazine,
was poorly tolerated in this population and led to frequent
adverse events. Overall, our ﬁndings are consistent with those
of NEAT-HFpEF (Nitrate’s Effect on Activity Tolerance in Heart
Failure with Preserved Ejection Fraction) trial, which showed
that isosorbide mononitrate decreased physical activity on
accelerometry and led to numerically greater adverse events
as compared with PB.52 While patients in NEAT-HFpEF were
predominantly white women, as opposed to our predom-
inantly black male population, the consistency of the ﬁndings
suggests that the addition of hydralazine to organic nitrate
therapy, a useful therapeutic approach in HFrEF,28 is not a
suitable approach in HFpEF. In particular, the increased wave
reﬂections, increased EDV, worsened exercise capacity, and
poor tolerability observed in our trial argue against a potential
beneﬁt of this drug combination in HFpEF.
Interestingly, in contrast to organic nitrate, inorganic
nitrate and nitrite have been shown to reduce wave reﬂec-
tions,53,54 improve endothelial function,53 blunt the exercise-
induced rise in pulmonary capillary wedge pressure,55 and
enhance exercise capacity in 2 separate trials of patients with
HFpEF.56,57 The effects of sustained administration of inor-
ganic nitrate (KNO3) in HFpEF are currently being examined in
a phase IIb trial sponsored by the National Heart, Lung, and
Blood Institute (KNO3CK OUT HFPEF trial, ClinicalTrials.gov:
NCT02840799). A trial of inhaled inorganic nitrite in HFpEF is
also underway (ClinicalTrials.gov: NCT02713126).
Study Strengths and Limitations
Our study should be interpreted in the context of its strengths
and limitations. The strengths of our study include its double-
blinded randomized design, the use of state-of-the-art meth-
ods for central pressure and ﬂow assessments, hemodynamic
modeling, and the noninvasive characterization of myocardial
structure and function. Our study also has limitations, mainly
related to its small sample size. Despite ﬂexibility in
scheduling and compensation for participation,58,59 only 27
of 44 (61%) patients who started the study medications
completed the study. Unfortunately, the poor tolerability of
the study interventions themselves contributed to the
increased number of patients who prematurely left the study.
Of the 17 patients who withdrew after starting study
medications, 8 (47%) withdrew because of side effects
Table 7. AEs in Patients Who Started Study Medications
No. (%) ISDN (n=13)
ISDN+Hydral
(n=15)
Placebo
(n=16) P Value
Any AE 8 (61.5) 9 (60.0) 2 (12.5) 0.007
Treatment-related AE 6 (46.2) 6 (40.0) 1 (6.3)
Headache 4 (30.8) 2 (13.3) 1 (6.3)
GI symptoms 0 (0) 1 (6.7) 0 (0)
Dizziness/
lightheadedness
2 (15.4) 2 (13.3) 0 (0)
Hypotension 1 (7.7) 3 (20.0) 0 (0)
Orthostasis 1 (7.7) 2 (13.3) 0 (0)
Fatigue 0 (0) 1 (6.7) 0 (0)
Reduced renal
function
1 (7.7) 0 (0) 0 (0)
Discontinued study
medications due
to related AE
4 (30.8) 3 (20.0) 1 (6.3)
Treatment-unrelated
AE
2 (15.4) 6 (40.0) 1 (6.3)
GI symptoms 1 (7.7) 1 (6.7) 1 (6.3)
Reduced renal
function
0 (0) 0 (0) 1 (6.3)
Retinal hemorrhage 1 (7.7) 0 (0) 0 (0)
Bacterial pneumonia 0 (0) 1 (6.7) 0 (0)
Atrial fibrillation 0 (0) 2 (13.3) 0 (0)
Atypical chest pain 1 (7.7) 1 (6.7) 1 (6.3)
Cauda equina
syndrome
0 (0) 0 (0) 1 (6.3)
Cellulitis 0 (0) 1 (6.7) 0 (0)
Rhabdomyolysis 0 (0) 0 (0) 1 (6.3)
AE indicates adverse event; GI, gastrointestinal; Hydra, hydralazine; ISDN, isosorbide
dinitrate.
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(ISDN=4, ISDN+hydral=3, PB=1). Unlike NEAT-HFpEF, we
enrolled a predominantly black population (61%). Recruitment
and retention of black patients within clinical trials represent
an important yet challenging consideration.59 Future studies
in this population should consider strategies to improve
retention, such as involvement of community leaders,
greater utilization of research nurses, and more intensive
follow-up.58,59
The dose of study medications may also have had an
impact on their tolerability. The NEAT-HFpEF investigators
noted decreased activity starting at low doses of organic
nitrate (isosorbide mononitrate, 30 mg/d), suggesting that
even low doses may have untoward effects.60 In addition, our
population was predominantly black and male, limiting
generalizability to the overall HFpEF population. However,
black patients represent a unique group, with impaired
endothelial function and nitric oxide bioavailability noted in
health,61,62 hypertension,63 and HFrEF.64 That the combina-
tion of organic nitrate and hydralazine did not reduce wave
reﬂections in this population suggests that it is unlikely to do
so in other HFpEF populations.
Conclusions
Despite the small sample size, the high incidence of adverse
events and the within-group changes demonstrated in the
active arms in our study do not support the use of ISDN, with
or without hydralazine, in patients with HFpEF.
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